GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » Gross Profit

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Gross Profit : $1,329 Mil (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Sartorius Stedim Biotech Gross Profit?

Sartorius Stedim Biotech's gross profit for the three months ended in Dec. 2023 was $276 Mil. Sartorius Stedim Biotech's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $1,329 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Sartorius Stedim Biotech's gross profit for the three months ended in Dec. 2023 was $276 Mil. Sartorius Stedim Biotech's Revenue for the three months ended in Dec. 2023 was $771 Mil. Therefore, Sartorius Stedim Biotech's Gross Margin % for the quarter that ended in Dec. 2023 was 35.81%.

Sartorius Stedim Biotech had a gross margin of 35.81% for the quarter that ended in Dec. 2023 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Sartorius Stedim Biotech was 53.79%. The lowest was 44.44%. And the median was 51.63%.

Warning Sign:

Sartorius Stedim Biotech SA gross margin has been in long-term decline. The average rate of decline per year is -2.1%.


Sartorius Stedim Biotech Gross Profit Historical Data

The historical data trend for Sartorius Stedim Biotech's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Gross Profit Chart

Sartorius Stedim Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 831.43 1,220.59 1,754.80 1,925.21 1,345.15

Sartorius Stedim Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 483.05 400.96 352.00 299.89 276.01

Competitive Comparison of Sartorius Stedim Biotech's Gross Profit

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Gross Profit distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Gross Profit falls into.



Sartorius Stedim Biotech Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Sartorius Stedim Biotech's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=3026.718 - 1681.571
=1,345

Sartorius Stedim Biotech's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=770.774 - 494.765
=276

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,329 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Sartorius Stedim Biotech's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=276 / 770.774
=35.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sartorius Stedim Biotech  (OTCPK:SDMHF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sartorius Stedim Biotech had a gross margin of 35.81% for the quarter that ended in Dec. 2023 => Competition eroding margins


Sartorius Stedim Biotech Gross Profit Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Address
Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Headlines